US2015086554A1PendingUtilityA1

Dual Variable Domain Immunoglobulin and Uses Thereof

69
Assignee: ABBVIE INCPriority: Aug 19, 2005Filed: Oct 27, 2014Published: Mar 26, 2015
Est. expiryAug 19, 2025(expired)· nominal 20-yr term from priority
A61P 7/06A61P 9/00A61P 9/10A61P 3/10A61P 37/06A61P 37/08A61P 41/00A61P 35/02A61P 25/16A61P 35/00A61P 29/00A61P 31/18A61P 25/28A61P 31/12A61P 25/24A61P 25/18A61P 25/06A61P 31/00A61P 31/04A61P 25/00A61P 25/32C07K 16/2887C07K 16/245C07K 16/467C07K 2317/51C07K 16/2896A61K 47/42A61P 13/12C07K 16/40C07K 2317/24A61P 21/02A61P 19/02C07K 2317/76A61P 21/00A61P 1/00A61K 2039/505A61P 23/00C07K 16/2809C07K 16/244A61P 17/06C07K 16/24A61P 19/04C07K 16/241A61P 19/10A61P 17/00C07K 2317/31C07K 16/468C07K 2317/64A61K 51/1093C07K 2317/56A61K 45/06A61P 11/00A61K 39/3955A61P 1/16C07K 2317/522A61P 15/00C07K 16/46A61P 11/06C07K 16/22Y02A50/30
69
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A method for treating a human subject for a disease or a disorder by administering to the subject a binding protein comprising four polypeptide chains wherein:
 each of two polypeptide chains comprises VD1-(X1)n-VD2-C-(X2)n, wherein VD1 is a first heavy chain variable domain, VD2 is a second heavy chain variable domain, C is a constant domain, X1 is a linker with the proviso that it is not a constant domain, X2 is an Fc region, and n is 0 or 1; and   each of two polypeptide chains comprises VD1-(X1)n-VD2-C, wherein VD1 is a first light chain variable domain, VD2 is a second light chain variable domain, C is a constant domain, and X1 is a linker with the proviso that it is not a constant domain, and n is 0 or 1;   wherein the four polypeptide chains of the binding protein form four functional target binding sites; and   wherein the binding protein binds a target or targets that are detrimental to the human subject suffering from the disease or disorder such that the activity of the target or targets in the human subject is inhibited such that treatment is achieved.   
     
     
         2 . The method of  claim 1 , wherein the step of administering to the subject is by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intraarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.